Editorial Podcasts

Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, talks about the effects of COVID on worldwide biomanufacturing, and what the repatriation of pharma could look like.

Scott Nawrocki, managing director of digital investigations and cyber defense at Nardello & Co., discusses cybersecurity in pharma, including topics from prevention to crisis management.

Editorial Director, Lisa Henderson; European and online editor, Julian Upton; Senior Editor, Elaine Quilici ;and Assistant Editors of Pharmaceutical Executive, Miranda Schmalfuhs and Andy Studna, discuss some exciting industry trends for 2021, which they recently wrote for the January issue.

Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like.

Rich Horgan, founder and president of Cure Rare Disease (CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.

Sacha Ward, chief client officer of Point of Care Network, discusses how COVID has affected the roles of nurse practitioners and physician assistants, and why marketing managers should take a moment to understand this growing group of health care influencers.

Krystle Buntemeyer, president of SCORR Marketing, and Bharat Mehta, co-founder of PharmaCompass, discuss a new, free online tool called Pipeline Prospector, which they recently launched in collaboration.

Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.

George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.

Jack Khattar, president and CEO of Supernus Pharmaceuticals, talks about his experience bringing ADHD drugs to market in a challenging environment.

Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times.

Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.

Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing a company through COVID-19, in light of the fact that he himself is immunocompromised.

Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.

Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Senior Vice President of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.

Senior Editor, Elaine Quilici interviews Pratap Khedkar, managing principal of ZS Associates. Pratap talks about pharma’s scenario planning amid COVID-19 as it looks to settle into a new normal.

Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.

Chris Paquette, DeepIntent co-founder and CEO, talks about the evolution of digital marketing in pharma, specifically, how to approach data and technology usage in a privacy-first world.

Barbara Ryan, founder of Barbara Ryan Advisors, a member of PharmExec’s editorial advisory board, and the founder of Fabulous Pharma Females discusses the strong community she’s built providing women the opportunity to connect with each other and reinforce their shared commitment to one another.

Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.

Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.

Mike Strazzella, head of federal government relations for Buchanan Ingersoll & Rooney, talks about pricing issues in the pharmaceutical industry, the challenges he encounters, and what he believes needs to change in the industry going forward.

Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.

Pharm Exec editors discuss the themes chosen for the January issue focusing on industry trends for the coming year.